Technical Analysis for SPHRF - Starpharma Holdings

Grade Last Price % Change Price Change
grade D 0.83 -4.60% -0.0400
SPHRF closed down 4.6 percent on Friday, December 20, 2019, on 59 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical SPHRF trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Down Weakness 0.00%
Bollinger Band Squeeze Range Contraction -4.60%
Narrow Range Bar Range Contraction -4.60%
Crossed Above 50 DMA Bullish -4.60%
Bollinger Band Squeeze Range Contraction -4.60%
Older signals for SPHRF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company based in Australia with established commercial partnerships and products launched, or nearing launch, within the pharmaceutical, sexual health and agrochemical sectors. Starpharma has developed a diverse portfolio of compelling products based on an underlying technology built around dendrimers. Starpharma's most advanced products are based on VivaGel (SPL7013, astodrimer sodium), a proprietary dendrimer which has antimicrobial properties. VivaGel has been developed as two discrete products for bacterial vaginosis (BV), firstly for the treatment of BV, and secondly, for the prevention of recurrent BV. These breakthrough products target areas of significant unmet medical need in high-value markets. The VivaGel range includes the world™s first and only antiviral condom (licensed to several partners). Starpharma revolutionary DEP technology is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP versions of existing drugs, particularly in the area of anti-cancer. DEP partnerships include multiple programs with AstraZeneca and other world leading pharmaceutical companies. Starpharma also has agrochemical programs to enhance agricultural formulations. Starpharma has an IP portfolio of 100+ patents. The Starpharma HQ and research facilities are located in Melbourne Australia.
Health Medical Specialties Biopharmaceutical Pharmaceuticals Pharmaceutical Pharmaceutical Industry In China Astrazeneca Antiseptics Sexually Transmitted Diseases And Infections Bacterial Vaginosis Prevention Of Hiv/Aids Dendrimer Dendrimers Dep Technology Microbicides Microbicides For Sexually Transmitted Diseases Starpharma Hq Underlying Technology

Is SPHRF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.3
52 Week Low 0.4719
Average Volume 1,698
200-Day Moving Average 0.0000
50-Day Moving Average 0.8653
20-Day Moving Average 0.8666
10-Day Moving Average 0.8603
Average True Range 0.0207
ADX 11.0
+DI 44.4483
-DI 53.2269
Chandelier Exit (Long, 3 ATRs ) 0.8379
Chandelier Exit (Short, 3 ATRs ) 0.8122
Upper Bollinger Band 0.9039
Lower Bollinger Band 0.8293
Percent B (%b) 0.01
BandWidth 8.6084
MACD Line 0.0010
MACD Signal Line 0.0022
MACD Histogram -0.0012
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.8300
Resistance 3 (R3) 0.8300 0.8300 0.8300
Resistance 2 (R2) 0.8300 0.8300 0.8300 0.8300
Resistance 1 (R1) 0.8300 0.8300 0.8300 0.8300 0.8300
Pivot Point 0.8300 0.8300 0.8300 0.8300 0.8300
Support 1 (S1) 0.8300 0.8300 0.8300 0.8300 0.8300
Support 2 (S2) 0.8300 0.8300 0.8300 0.8300
Support 3 (S3) 0.8300 0.8300 0.8300
Support 4 (S4) 0.8300